| 0.7017 -0.05 (-6.7%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.15 |
1-year : | 1.37 |
| Resists | First : | 0.99 |
Second : | 1.17 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.68 |
Second : | 0.57 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.91 |
| MA(100) : | 1.04 |
MA(250) : | 113.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 9.4 |
| RSI | RSI(14): 24.3 |
|||
| 52-week | High : | 1200 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PLRZ ] has closed above bottom band by 10.8%. Bollinger Bands are 8.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.76 | 0.76 - 0.76 |
| Low: | 0.67 - 0.68 | 0.68 - 0.68 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Thu, 14 Aug 2025
Polyrizon regains compliance with Nasdaq listing requirements - Investing.com
Thu, 14 Aug 2025
Polyrizon Secures Future on Nasdaq as Stock Meets Minimum Price Requirements - Stock Titan
Tue, 22 Jul 2025
Polyrizon Achieves Breakthrough in Allergy Blocker Study - TipRanks
Tue, 22 Jul 2025
Polyrizon stock soars after promising nasal allergy blocker test results - Investing.com
Tue, 15 Jul 2025
Polyrizon secures continued Nasdaq listing after panel hearing - Investing.com
Tue, 15 Jul 2025
Polyrizon Ltd. Secures Continued Nasdaq Listing Following Compliance Plan Implementation - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 139 (K) |
| Shares Short P.Month | 371 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -12.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -3.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|